Introduction
============

Cardiovascular disease (CVD) is the most common disease in developing countries. Nearly 23.6 million people will die from CVDs and coronary artery disease (CAD) will become the leading cause of death by 2030 ([@B1], [@B2]).

Hyperinsulinemia resulted from insulin resistance is a valuable prediction factor in CAD disease ([@B3], [@B4]). Insulin resistance can increase blood fibrinogen ([@B5]) and is closely associated with salt-sensitive type of hypertension in obese and non-obese patients; and therefore, can increase individual vulnerability to cardiovascular diseases ([@B6]).

Changes in lifestyle and also consumption of some dietary supplements have a critical role in managing of many chronic diseases ([@B7]). For example, diets reduced in total fat can prevent CVD ([@B8]) and high levels of monounsaturated fatty acids (MUFA) and some polyunsaturated fatty acids (PUFA) can reduce the risk of CVD ([@B9]). Relatively, Mediterranean diets rich in fish oil and other marine sources of omega 3 fatty acids can decrease the risk of CHD mortality ([@B10]).

Omega 3 supplementation can improve endothelial function and decrease serum endothelial dysfunction markers such as E-selectin, I-CAM and V-CAM ([@B11], [@B12]). In some studies, consumption of omega 3 fatty acids was associated to increased risk of type 2 diabetes ([@B13], [@B14]); however, other studies did not show such an association ([@B15], [@B16]). Omega 3 supplementation has resulted in a significant decrease in insulin resistance in several studies ([@B17]). This decrease seems to be linked to changes in adiponectin ([@B18]) and also activation of AMPK pathway ([@B19]).

Vitamin E is an important nutrient and can develop beneficial effects in patients with heart diseases. This vitamin is an antioxidant and can possibly decrease oxidative stress. Vitamin E also is an anti-inflammatory agent and can decrease inflammatory factors such as IL-1β and IL-6 ([@B20], [@B21]).

Effects of omega 3 and vitamin E co-administration on insulin resistance and glucose homeostasis have been less described in previous studies. Therefore, the current study was carried out to assess possible effects of omega 3 alone and combined omega 3 and vitamin E supplementations on serum lipid profile and glucose homeostasis in CAD patients.

Methods
=======

Sixty-five non-smoker male patients with CAD were participated in this randomized double-blind placebo-controlled clinical trial. All participants had at least 50% stenosis in one coronary artery and were selected from the Heart Medical Center of Tehran, Tehran, Iran. Participants signed an informed consent before the study. Furthermore, this study was registered in [www.clinicaltrial.org](www.clinicaltrial.org) under the registry number of NCT02011906 and approved by the Ethical Committee of Tehran University of Medical Sciences (ID: 23605).

All patients had BMI ≤ 30 and none of them had history of kidney and liver disorders, diabetes and thyroid malfunction. Patients were divided randomly into three groups including OP group received 4 g/day of omega-3 fatty acids and vitamin E placebo, OE group received 4 g/day of omega-3 fatty acid soft gels and 400 IU of vitamin E, and PP group received omega-3 fatty acids and vitamin E placebos. The contents of DHA and EPA in each gram of omega 3 soft gels were respectively 120 and 180 mg. Supplementation continued for eight months. Supplements and placebos used in this study were supplied by Minoo Pharmaceutical, Cosmetic and Hygienic Company, Iran.

Anthropometric measurements were carried out before and after the intervention. Weight was measured closely to the nearest 0.1 kg with minimal clothing and no shoes. Height, hip and waist circumferences were measured to the nearest 0.1 cm. BMI was calculated as the weight in kg divided by the square of height in meter. Waist to hip ratio (WHR) was calculated by dividing the circumference of waist to the circumference of hip.

Dietary information of the patients was obtained using a 2-day food recall filled before the beginning and after finishing off the intervention. Ten milliliters of blood were collected from the patients after 12 to14 h of overnight fasting. Then, serum samples were separated and stored at −80 °C until use. Fasting serum glucose, total cholesterol, HDL-C, LDLC and triglyceride concentrations were assessed using commercial kits (Pars Azmoon, Iran). Serum insulin was assessed using ELISA method (Diametra, Italy) with the sensitivity of 0.25 mcIU/ml and HOMA-IR was calculated by fasting glucose (mg/dl) multiplied by fasting insulin (μIU/ml)/405 ([@B22]).

Dietary data were analyzed using Nutritionist IV Software and statistical analysis was carried out using SPSS Software v18. All data were shown as mean ±SE (standard error) of the parameter. Normality of the parameter distribution was checked using Kolmogorov-Smirnoff test. Oneway analysis-of-variance (ANOVA) test and paired t-test were used respectively to compare the mean of variables between and within the groups before and after the intervention. Significance was considered when *P-*values ≤ 0.05.

Results
=======

At the beginning of the study, 65 male CAD patients were participated in the clinical trial. However, three patients were hospitalized for heart surgery during the intervention and two patients consumed less than 90% of the total supplements and hence, were excluded from the study. Therefore, the study was carried out with 60 patients, as 20, 21 and 19 patients were included in OE, OP and PP groups, respectively. Patients in these groups were not statistically different from each other in mean ages and disease duration at the baseline of the study (*P*= 0.079 and *P*= 0.299, respectively).

[Table 1](#T1){ref-type="table"} describes the baseline anthropometric measurements of the three groups at the beginning of intervention. No significant differences were seen between the means of weight, BMI and other anthropometric parameters of the study groups at the baseline. Dietary intakes of the three groups are shown in [Table 2](#T2){ref-type="table"}. Food recall analysis of the patients revealed that no significant differences existed between energy and macronutrient intakes in OP, OE and PP groups at the baseline and at the end of the intervention. Furthermore, the intakes of vitamin E and different fatty acids were not different between study groups and they were not changed their routine dietary patterns during the intervention.

###### 

Basic anthropometric parameters of the study groups before the intervention

  **Variable**               **OE (*n* = 21)**   **OP (*n* = 20)**   **PP (*n* = 19)**   ***P*-value[^\*^](#TFN2){ref-type="table-fn"}**
  -------------------------- ------------------- ------------------- ------------------- -------------------------------------------------
  Height (cm)                170.32 ±1.19        169.04 ±1.36        170.92 ±1.58        0.623
  Weight (kg)                78.54 ±2.17         79.95 ±2.68         78.35 ±1.87         0.864
  BMI (kg/cm^2^)             27.08 ±0.70         27.95 ±0.83         26.85 ±0.61         0.530
  Waist circumference (cm)   95.76 ±1.58         98.72 ±2.11         96.18 ±1.88         0.479
  Hip circumference (cm)     100.33 ±1.15        101.12 ±1.59        99.63 ±0.80         0.701
  WHR                        0.95 ±0.01          0.97 ±0.01          0.96 ±0.01          0.463

OP, omega-3 fatty acid and placebo; OE, omega-3 fatty acid and vitamin E; PP, placebo and placebo; BMI, body mass index; WHR; waist to hip ratio;

ANOVA analysis

###### 

Dietary intakes of the study groups before and after the intervention

  **Treatment group**                                                        **OE (*n* = 21)**   **OP (*n* = 20)**   **PP (*n* = 19)**   ***P*-value[^\*^](#TFN4){ref-type="table-fn"}**
  --------------------------- ---------------------------------------------- ------------------- ------------------- ------------------- -------------------------------------------------
  Energy (Kcal)               Baseline                                       1469.10 ±93.33      1450.74 ± 114.37    1528.49 ±111.25     0.867
                              Post-intervention                              1649.48 ±122.47     1684.55 ±131.39     1508.20 ±130.59     0.596
                              difference                                     180.38 ±162.53      233.81 ±169.99      32.36 ±173.82       0.688
                              *P*-value[^\#^](#TFN5){ref-type="table-fn"}    0.281               0.185               0.854               
  Carbohydrate (g)            Baseline                                       228.44 ±16.93       231.47 ±22.93       246.01 ±18.52       0.800
                              Post-intervention                              259.51 ±21.96       271.56 ±25.45       238.00 ±21.37       0588
                              difference                                     31.06 ±25.68        40.09 ±26.02        −8.01 ±30.04        0.426
                              *P*-value[^\#^](#TFN5){ref-type="table-fn"}    0.241               0.140               0.793               
  Protein (g)                 Baseline                                       69.64 ±8.76         62.25 ±7.75         62.27 ±7.71         0.770
                              Post-intervention                              66.16 ±6.98         60.44 ±5.74         59.30 ±6.49         0.722
                              difference                                     −3.48 ±11.49        −1.81 ±10.58        3.42 ±10.64         0.992
                              *P*-value[^\#^](#TFN5){ref-type="table-fn"}    0.765               0.866               0.751               
  Fat (g)                     Baseline                                       33.45 ±2.96         33.05 ±2.79         35.08 ±3.82         0.895
                              Post-intervention                              41.80 ±4.10         42.88 ±3.75         37.01 ±3.86         0.538
                              difference                                     8.34 ±5.28          9.82 ±4.97          1.93 ±5.53          0.538
                              *P*-value[^\#^](#TFN5){ref-type="table-fn"}    0.131               0.063                                   
  Vitamin E (mg)              Baseline                                       2.72 ±0.74          2.70 ±0.55          2.29 ±0.65          0.427
                              Post-intervention                              4.04 ±0.97          4.19 ±1.04          2.77 ±0.45          0.311
                              difference                                     1.33 ±1.35          1.48 ±1.29          0.48 ±0.78          0.971
                              *P*-value[^\#^](#TFN5){ref-type="table-fn"}    0.338               0.265               0.456               
  Omega-3 fatty acids (g)     Baseline                                       0.13 ±0.04          0.12 ±0.03          0.11 ±0.04          0.963
                              Post-intervention                              0.11±0.05           0.21 ±0.10          0.10 ±0.03          0.464
                              difference                                     −0.01±0.06          0.09 ±0.11          −0.01 ±0.05         0.570
                              *P*-value[^\#^](#TFN5){ref-type="table-fn"}    0.821               0.428               0.781               
  Omega 6 fatty acids (g)     Baseline                                       10.80 ±1.17         11.47 ±0.93         10.89 ±1.76         0.926
                              Post-intervention                              13.58 ±2.15         13.76 ±1.95         12.87 ±2.19         0.148
                              difference                                     2.78 ±2.59          2.29 ±2.21          1.98 ±2.91          0.534
                              *P*. value[^\#^](#TFN5){ref-type="table-fn"}   0.380               0.273               0.506               
  Saturated fatty acids (g)   Baseline                                       9.73 ±1.05          8.17 ±6.28          10.33 ±1.19         0.333
                              Post-intervention                              8.98 ±0.77          9.16 ±0.80          10.11 ±1.13         0.649
                              difference                                     −0.75 ±1.28         0.99 ±1.07          −0.22 ±1.65         0.643
                              *P*-value[^\#^](#TFN5){ref-type="table-fn"}    0.566               0.367               0.897               

OE, omega-3 fatty acid and vitamin E; OP, omega-3 fatty acid and placebo; PP, placebo and placebo;

ANOVA analysis;

paired T test

[Table 3](#T3){ref-type="table"} demonstrates fasting serum levels and HOMA-IR index in the study groups at the baseline and at the end of the supplementation. Serum levels of FBS increased significantly in patients receiving omega supplement (*P*=0.004). The patients were not statistically different in mean FBS at the end of the intervention. OE and OP groups showed a significant decrease in fasting serum TG (*P*=0.020 and *P*=0.001, respectively). Serum TG did not change significantly in PP group. Serum level of insulin and HOMA-IR decreased significantly in OE group (*P*=0.044 and *P*=0.039, respectively), but not in OP or PP group. Furthermore, the means of serum insulin level and HOMA-IR were significantly different between the study groups at the end of the intervention (*P*=0.032 and *P*=0.023, respectively). Post-hoc analysis (Tukey Test) showed no significant differences between the mean of serum insulin level and HOMA-IR in OE and OP groups (*P*=0.029 and *P*=0.019, respectively). Serum levels of LDL, HDL and TC did not change significantly within or between the study groups. However, differences were not significant statistically after adjusting BMI and disease duration.

###### 

Serum biochemical characteristics in the study groups before and after the intervention

  **Treatment group**                                                 **OE (*n* = 21)**   **OP (*n* = 20)**   **PP (*n* = 19)**   ***P*-value[^\*^](#TFN7){ref-type="table-fn"}**
  --------------------- --------------------------------------------- ------------------- ------------------- ------------------- -------------------------------------------------
  FBS (mg/dl)           Baseline                                      92.19 ±3.27         87.75 ±3.25         89.32 ±4.78         0.697
                        Post-intervention                             89.38 ±2.32         99.13 ±3.78         94.5 ±3.53          0.108
                        difference                                    2.81 ±3.79          11.37 ±3.46         4.74 ±4.13          0.034
                        *P*-value[^\#^](#TFN8){ref-type="table-fn"}   0.264               0.004               0.267               
  TG (mg/dl)            Baseline                                      185.48 ±17.39       180.38 ±18.02       174.53 ±19.41       0.914
                        Post-intervention                             145.38 ±9.44        131.28 ±14.53       154.58 ±19.87       0.458
                        difference                                    −40.10 ±15.92       −49.10 ±12.25       −19.95 ±12.25       0.325
                        *P*-value[^\#^](#TFN8){ref-type="table-fn"}   0.020               0.001               0.121               
  TC (mg/dl)            Baseline                                      186.57 ±8.71        157.95 ±7.79        170.47 ±15.85       0.190
                        Post-intervention                             165.00 ±12.35       154.55 ±6.16        169.76 ±10.87       0.568
                        difference                                    −21.57 ±16.04       −3.40 ±9.09         −0.71 ±13.69        0.484
                        *P*-value[^\#^](#TFN8){ref-type="table-fn"}   0.194               0.713               0.959               
  LDL (mg/dl)           Baseline                                      109.90 ±4.38        100.10 ±3.77        105.21 ±5.26        0.302
                        Post-intervention                             107.14 ±6.60        95.40 ±4.05         109.21 ±5.93        0.189
                        difference                                    −2.76 ±7.43         −4.70 ±3.94         4.00 ±3.836         0.512
                        *P*-value[^\#^](#TFN8){ref-type="table-fn"}   0.311               0.248               0.714               
  HDL (mg/dl)           Baseline                                      34.35 ±1.92         31.30 ±1.66         34.42 ±1.89         0.394
                        Post-intervention                             37.14 ±2.38         35.55 ±1.62         37.95 ±1.95         0.702
                        difference                                    2.73 ±2.03          4.25 ±2.21          3.52 ±0.97          0.854
                        *P-*value[^\#^](#TFN8){ref-type="table-fn"}   0.120               0.065               0.182               
  Insulin (μIU/ml)      Baseline                                      9.96 ±0.88          13.64 ±1.79         10.74 ±1.21         0.129
                        Post-intervention                             9.09 ±0.71          13.83 ±1.92         10.38 ±0.90         0.032
                        difference                                    −0.86 ±0.40         0.185 ±1.35         −0.36 ±0.86         0.729
                        *P-*value[^\#^](#TFN8){ref-type="table-fn"}   0.044               0.893               0.678               
  HOMA-IR               Baseline                                      2.28 ±0.24          2.97 ±0.39          2.48 ±0.36          0.339
                        Post-intervention                             2.02 ±0.20          3.45 ±0.54          2.46 ±0.27          0.023
                        difference                                    0.48 ±0.37          −0.25 ±0.12         0.02 ±0.25          0.142
                        *P-*value[^\#^](#TFN8){ref-type="table-fn"}   0.039               0212                0.931               

OE, omega-3 fatty acid and vitamin E; OP, omega-3 fatty acid and placebo; PP, placebo and placebo; hsCRP, high-sensitivity C-reactive protein;

ANOVA analysis;

paired T test

Discussion
==========

In the current study, omega 3 supplementation alone or in combination with vitamin E significantly decreased serum TG levels in OE and OP groups. Supplementation with omega 3 fatty acids can include a dose-dependent effect on serum triglycerides and reduce its concentration up to 30% ([@B23], [@B24]). These fatty acids seem to be able to inhibit the production of TG and apolipoprotein B by the liver ([@B25]). Furthermore, these fatty acids can increase fatty acid oxidation by mitochondria ([@B23]). Serum glucose levels have increased significantly in patients receiving omega 3 supplements alone; however, the level was in normal range. This increase was not seen in OE group.

Therefore, the question was if omega 3 fatty acid supplements could include adverse effects on glucose homeostasis. Effects of omega 3 fatty acids on serum glucose level have been conflicting in various studies. While, omega 3 supplementation was previously shown to adversely influence glucose homeostasis ([@B26], [@B27]), these fatty acids can increase glucose uptake and improve insulin sensitivity ([@B28], [@B29]). An experimental study on rats has demonstrated that consumption of fish oil can prevent insulin resistance induced by high-fat feeding ([@B30]). In contrast, results of the current study revealed that serum insulin level and HOMA-IR index did not change significantly in patients receiving omega 3 supplements only. Interestingly, these parameters decreased significantly in OE group. However, the mechanism for this is not clearly explained, it is possibly associated to use of vitamin E.

Vitamin E can improve glucose homeostasis because it can influence insulin sensitivity ([@B31], [@B32]). Indeed, oxidative stress is a key factor in development of insulin resistance and vitamin E with its ROS scavenger ability can positively affect insulin action and glycemic control ([@B33]). Another mechanism, which links vitamin E to insulin resistance, is the anti-inflammatory property of this vitamin. Inflammatory cytokines such as TNF-α and IL-1β have been shown to induce insulin resistance. TNF-α can increase adipocyte lipolysis and serine/threonine phosphorylation of IRS-1 and IL-1β can increase CRP level via elevating IL-6 and impair signaling of insulin in peripheral tissues which can result in reduced insulin sensitivity and impair insulin secretion ([@B34], [@B35]). Both α and γ-tocopherol forms of vitamin E include anti-inflammatory effects and can reduce serum level of CRP ([@B36]).

Conclusion
==========

Supplementation with combined omega 3 fatty acids and vitamin E includes beneficial effects on serum insulin level and HOMA-IR and co-administration of these supplements can be a good strategy against development of insulin resistance seen in CAD patients.
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